FDG PET in lymphoma: The need for standardization of interpretation. An observer variation study
- 1 October 2007
- journal article
- research article
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 28 (10), 798-803
- https://doi.org/10.1097/mnm.0b013e3282eff2d5
Abstract
To measure and describe patterns of interobserver variation in visual interpretation of 18F-FDG PET in malignant lymphoma. Eleven nuclear medicine physicians with different levels of PET experience independently reviewed 37 18F-FDG PET scans of lymphoma patients (10 obtained at presentation, 27 during or after therapy). They were requested to identify and localize suspicious lymphoma sites and to assign a stage to the baseline scans, and to interpret the remaining scans for the presence of viable lymphoma. Individual (extra-)nodal regions were assessed for the likelihood of malignancy as positive, negative or equivocal. These results were compared to expert readings after dichotomization in conservative and sensitive reading classifications. Sixty-one percent and 56% (using sensitive and conservative reading, respectively) of the baseline scans were scored in accordance with the experts. Fourteen of the 27 scans obtained for therapy evaluation with viable tumour sites were scored in accordance with the experts in 82% and 94% of the patients, using conservative and sensitive reading, respectively. The 13 negative scans were scored in agreement with the experts in only 45% of the cases. False positivity pertained especially to the neck, periclavicular, axilla, mediastinum, lung and bone marrow. More experienced observers tended to have fewer false negative scores. There are substantial disparities among nuclear medicine physicians' interpretations of FDG PET scans of lymphoma patients, which may affect patient care and results of multi-institutional clinical trials. A well-defined set of criteria is urgently needed to improve consistency.Keywords
This publication has 10 references indexed in Scilit:
- Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretationNuclear Medicine Communications, 2005
- 18F-FDG PET in malignant lymphoma: significance of positive findingsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2005
- Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphomaBritish Journal of Cancer, 2004
- 18FDG positron emission tomography versus 67Ga scintigraphy as prognostic test during chemotherapy for non‐Hodgkin's lymphomaBritish Journal of Haematology, 2003
- PET for staging of Hodgkin's disease and non-Hodgkin's lymphomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003
- PET in lymphoma: what are the oncologist's needs?European Journal of Nuclear Medicine and Molecular Imaging, 2003
- [18F]FDG PET monitoring of tumour response to chemotherapy: does [18F]FDG uptake correlate with the viable tumour cell fraction?European Journal of Nuclear Medicine and Molecular Imaging, 2003
- Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphomaAnnals of Oncology, 2002
- Interobserver Variability in the Detection of Cervical-Thoracic Hodgkin's Disease by Computed TomographyJournal of Clinical Oncology, 1999
- Radiology's Achilles' heel: error and variation in the interpretation of the Röntgen image.The British Journal of Radiology, 1997